Kyverna Therapeutics (KYTX) Stock Forecast & Price Target

$9.84

+0.94 (+10.56%)

(As of 07/26/2024 ET)

Kyverna Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy
Based on 6 Analyst Ratings

Based on 6 Wall Street analysts who have issued ratings for Kyverna Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 6 analysts, 1 has given a hold rating, and 5 have given a buy rating for KYTX.

Consensus Price Target

$35.80
263.82% Upside

High Forecast	$48.00
Average Forecast	$35.80
Low Forecast	$8.00

According to the 6 analysts' twelve-month price targets for Kyverna Therapeutics, the average price target is $35.80. The highest price target for KYTX is $48.00, while the lowest price target for KYTX is $8.00. The average price target represents a forecasted upside of 263.82% from the current price of $9.84.

Type	Current Forecast 7/28/23 to 7/27/24	1 Month Ago 6/28/23 to 6/27/24	3 Months Ago 4/29/23 to 4/28/24	1 Year Ago 7/28/22 to 7/28/23
Consensus Rating	Moderate Buy	Buy	Buy	N/A
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	N/A
Buy	5 Buy rating(s)	5 Buy rating(s)	5 Buy rating(s)	N/A
Hold	1 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	N/A
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	N/A
Consensus Price Target	$35.80	$42.75	$42.75	N/A
Forecasted Upside	263.82% Upside	54.05% Upside	54.05% Upside	N/A

Get Kyverna Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for KYTX and its competitors with MarketBeat's FREE daily newsletter.

Ad American Hartford Gold Group

Prepare for a Recession Unlike Any Other

Dave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.

GET THE FREE GUIDE

KYTX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

KYTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Kyverna Therapeutics Stock vs. The Competition

Type	Kyverna Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.83	2.72	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	263.82% Upside	3,123.46% Upside	9.17% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
7/16/2024	HC Wainwright 3 of 5 stars	M. Kapoor Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$8.00 ➝ $8.00	-19.27%
3/4/2024	Leerink Partnrs 0 of 5 stars	T. Smith Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
3/4/2024	Wells Fargo & Company 3 of 5 stars		Initiated Coverage	Overweight	$44.00	+58.56%
3/4/2024	SVB Leerink Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$48.00	+72.97%
3/4/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Overweight	$40.00	+44.14%
3/4/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Overweight	$39.00	+40.54%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 07:09 AM ET.

KYTX Forecast - Frequently Asked Questions

What is Kyverna Therapeutics' forecast for 2024?: According to the research reports of 6 Wall Street equities research analysts, the average twelve-month stock price forecast for Kyverna Therapeutics is $35.80, with a high forecast of $48.00 and a low forecast of $8.00.
Should I buy or sell Kyverna Therapeutics stock right now?: 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kyverna Therapeutics in the last year. There is currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" KYTX shares.
Does Kyverna Therapeutics's stock price have much upside?: According to analysts, Kyverna Therapeutics's stock has a predicted upside of 48.04% based on their 12-month stock forecasts.
What analysts cover Kyverna Therapeutics?: Kyverna Therapeutics has been rated by research analysts at HC Wainwright in the past 90 days.
Do Wall Street analysts like Kyverna Therapeutics more than its competitors?: Analysts like Kyverna Therapeutics more than other "medical" companies. The consensus rating score for Kyverna Therapeutics is 2.83 while the average consensus rating score for "medical" companies is 2.72. Learn more on how KYTX compares to other companies.